Geninus Publishes Research Paper Utilizing Single-Cell Analysis in US Academic Journal JITC

Geninus, a genome analysis specialist company, announced on the 28th that its research results using single-cell analysis were published in the official journal of the Society for Immunotherapy of Cancer, the Journal for ImmunoTherapy of Cancer (hereinafter JITC).

The Society for Immunotherapy of Cancer (SITC), established in 1984, is a prestigious society in the field of immuno-oncology with over 4,600 scientists, researchers, and clinicians from 63 countries worldwide engaged in cancer research and treatment as its members.

The research published in JITC revealed the correlation between single-cell analysis results of immune cells present in patient blood and the response to immune checkpoint inhibitor drugs. Through this study, it is possible to predict the long-term effects of immune checkpoint inhibitors based on the proportion of specific immune cells in the patient’s blood from the early stages of drug administration. The research was jointly conducted by Geninus CEO Woongyang Park, Professors Sehoon Lee and Sehoon Park, researcher Hyunsoo Kim, and the hematology-oncology research team at Samsung Medical Center.

Geninus CEO Woongyang Park stated, “This paper is encouraging as it confirms that predicting individual immune drug responses through non-invasive methods can enable rapid establishment of treatment strategies such as drug selection.” He added, “Based on this research, we are pleased to demonstrate that Geninus’ renowned single-cell analysis service can be closely linked and utilized with the immune characteristics of individual patients beyond advanced research fields.”

Meanwhile, Geninus’ single-cell analysis platform used in this study, Celinus, provides a user-customized environment platform including sample preprocessing and tailored result interpretation reports. Geninus plans to launch Xenium, a service based on ISH (in situ Hybridization) technology, and expand its business area to single-cell CRO (Contract Research Organization) within this year.